Cybin Förvaltning

Förvaltning kriterier kontrolleras 2/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Mike Cola

Verkställande direktör

n/a

Total ersättning

VD-lön i procent	n/a
Anställning som VD	less than a year
Ägande av VD	n/a
Ledningens genomsnittliga anställningstid	4.8yrs
Styrelsens genomsnittliga mandatperiod	5.3yrs

Senaste uppdateringar av ledningen

Recent updates

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Feb 25

VD OCH KONCERNCHEF

Mike Cola (65 yo)

less than a year

Anställning

Mr. Michael F. Cola, also known as Mike, is Chief Executive Officer of Cybin Inc. from February 10, 2026. Mr. Cola is an Independent Chairman of Phathom Pharmaceuticals, Inc. He served as Chief Executive O...

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Eric So	Co-Founder	5.3yrs	US$6.84m	0.62% $ 2.3m
Paul Glavine	Co-Founder	no data	US$6.84m	0.56% $ 2.1m
Greg Cavers	Chief Financial Officer	5.3yrs	US$1.00m	0.038% $ 139.6k
Gabriel Fahel	Chief Legal Officer & Corporate Secretary	5.3yrs	US$1.12m	0.077% $ 282.6k
George Tziras	Chief Business Officer	2.4yrs	US$843.49k	0.072% $ 266.6k
Michael Cola	Chief Executive Officer	less than a year	inga uppgifter	inga uppgifter
John Kanakis	Co-Founder	no data	US$1.19m	inga uppgifter
Aaron Bartlone	Chief Operating Officer	2.7yrs	US$764.06k	0.069% $ 252.2k
Alex Nivorozhkin	Chief Scientific Officer	5.3yrs	inga uppgifter	inga uppgifter
Lori Challenger	Chief Compliance	4.4yrs	inga uppgifter	inga uppgifter
Sara Somerset	Chief Communications Officers	no data	inga uppgifter	inga uppgifter
Douglas Sommerville	Chief Pharmaceutical Strategist	no data	inga uppgifter	inga uppgifter

4.8yrs

Genomsnittlig anställningstid

49yo

Genomsnittlig ålder

Erfaren ledning: HELP s ledningsgrupp anses vara erfaren ( 4.8 års genomsnittlig anställningstid).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Eric So	Co-Founder	5.3yrs	US$6.84m	0.62% $ 2.3m
Paul Glavine	Co-Founder	5.3yrs	US$6.84m	0.56% $ 2.1m
Theresa Firestone	Lead Independent Director	4.6yrs	US$286.56k	0.052% $ 191.5k
Mark Lawson	Independent Director	5.3yrs	US$291.77k	0.056% $ 206.0k
Grant Froese	Independent Director	5.3yrs	US$271.58k	0.060% $ 222.4k
Eric Hoskins	Independent Director	5.3yrs	US$271.58k	0.055% $ 203.1k

5.3yrs

Genomsnittlig anställningstid

57.5yo

Genomsnittlig ålder

Erfaren styrelse: HELP s styrelse anses vara erfaren ( 5.3 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/03/01 13:19
Aktiekurs vid dagens slut	2026/02/27 00:00
Intäkter	2025/12/31
Årlig intjäning	2025/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Cybin Inc. bevakas av 13 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
James Molloy	Alliance Global Partners
David Martin	Bloom Burton & Co.
Sumant Satchidanand Kulkarni	Canaccord Genuity

Cybin Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Insider recently bought US$73k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Announces George Tziras Not Standing for Re-Election

Cybin Inc., Annual General Meeting, Aug 18, 2025

Recent updates

Helus Pharma Appoints Freda Lewis-Hall to Board of Directors and Chair of the Scientific Advisory Committee

HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2A Trial of Spl026 in Major Depressive Disorder

Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Inc. to Report Q2, 2026 Results on Nov 13, 2025

Cybin Inc. has completed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $175.009911 million.

Cybin Inc. Highlights Upcoming Clinical Milestones

Cybin Inc. Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Insider recently bought US$73k worth of stock

Cybin Inc. Announces Chief Executive Officer Changes

Cybin Inc. Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Announces George Tziras Not Standing for Re-Election

New major risk - Financial position

Cybin Inc. Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

New minor risk - Shareholder dilution

No longer forecast to breakeven

Cybin Inc. announced that it expects to receive $500 million in funding from High Trail Special Situations LLC

Cybin Inc., Annual General Meeting, Aug 18, 2025

Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

New minor risk - Share price stability

Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

No longer forecast to breakeven

New minor risk - Share price stability

Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin Inc. Announces Executive Appointments

Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones

Insufficient new directors

Forecast to breakeven in 2027

Cybin Inc. Announces the Realignment of the Composition of Governance and Nominating Committee, and Compensation Committee

Cybin Inc., Annual General Meeting, Aug 27, 2024

Co-Founder recently bought US$64k worth of stock

No longer forecast to breakeven

Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development

Forecast to breakeven in 2027

Cybin Inc. announced that it has received $150 million in funding from a group of investors

New minor risk - Profitability

Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder

Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. announced that it expects to receive $150 million in funding from a group of investors

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Inc. Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Inc. Announces the Presentation of Four Posters At the American College of Neuropsychopharmacology Annual Meeting

Cybin Inc. Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. has completed a Composite Units Offering in the amount of $30 million.

New major risk - Revenue and earnings growth

Cybin Inc. Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Cybin Inc. completed the acquisition of Small Pharma Inc. (TSXV : DMT).

Cybin Inc. Announces that George Tziras Joins the Board of Directors and Will Serve as Chief Business Officer

New major risk - Shareholder dilution

Cybin Inc. Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Cybin Inc. agreed to acquire Small Pharma Inc. (TSXV : DMT) for $23.2 million.

Cybin Inc. Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

New major risk - Financial position

Cybin Inc. has completed a Composite Units Offering in the amount of $8.25 million.

Cybin Inc. Announces Phase 2 Cohort 5 Dosing Completion of Cyb003 in Major Depressive Disorder

Cybin Inc. Announces Publication of Sponsored Feasibility Study Validating Kernel's Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin Inc. Announces the Development of Scalable Psychedelic Facilitation Training Program, Embarkct

New minor risk - Share price stability

Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer, Effective July 1, 2023

Cybin Inc., Annual General Meeting, Aug 29, 2023